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Abstract
Background: C-reactive protein (CRP) is a predictor of cardiovascular risk. It circulates as a pentameric protein in
plasma. Recently, a potential dissociation mechanism from the disc-shaped pentameric CRP (pCRP) into single
monomers (monomeric or mCRP) has been described. It has been shown that mCRP has strong pro-inflammatory
effects on monocytes. To further define the role of mCRP in determining monocyte phenotype, the effects of CRP
isoforms on THP-1 protein expression profiles were determined. The hypothesis to be tested was that mCRP
induces specific changes in the protein expression profile of THP-1 cells that differ from that of pCRP.
Methods: Protein cell lysates from control and mCRP, pCRP or LPS-treated THP-1 cells were displayed using
2-dimensional SDS PAGE and compared. Differentially expressed proteins were identified by MALDI-TOF MS and
confirmed by Western blotting.
Results: mCRP significantly up-regulates ubiquitin-activating enzyme E1, a member of the ubiquitin-proteasome
system in THP-1 monocytes. Furthermore, HSP 70, alpha-actinin-4 (ACTN4) and alpha-enolase/enolase 1 were
upregulated. The proteomic profile of LPS and pCRP treated monocytes differ significantly from that of mCRP.
Conclusion: The data obtained in this study support the hypothesis that isoform-specific effects of CRP may
differentially regulate the phenotype of monocytes.
Background
CRP is an acute phase reactant and member of the
evolutionary highly conserved pentraxin family. As such,
it consists of five non-covalently linked subunits of
~23 kDa. CRP can exist in at least two different confor-
mations, as a cyclic, disc-shaped pentamer of 115 kDa
(pCRP) that is circulating in plasma and as a monomeric
conformation termed modified or monomeric CRP
(mCRP). As a major source of mCRP, in vivo,w e
recently identified a mechanism of pCRP dissociation
localized on activated platelets and cells exposing bioac-
tive lipids, such as lysophosphatidylcholine [1].
pCRP and mCRP exhibit very distinct biological activ-
ities. Both CRP forms, however, display pro-inflamma-
tory effects. mCRP was found to be a considerably
more potent activator of endothelial cells and mono-
cytes than pCRP [1,2]. pCRP and mCRP exert opposing
effects on neutrophil trafficking into tissues [3] and pla-
telet and thrombus growth [4,5]. Other studies found
that pCRP induces pro-inflammatory cytokine release
from endothelial cells and monocytes and evokes
endothelial dysfunction and monocyte adhesion to the
endothelium [6].
Recently, we demonstrated that mCRP, but not pCRP,
is enriched in atherosclerotic plaques and is derived
from a localized dissociation process of the circulating
pCRP mediated by activated and apoptotic cell-
membranes [1]. This leads to a localized activation of
inflammatory cells, such as monocytes and the produc-
tion of reactive oxygen species within monocytes. Mono-
cytes are central in the pathogenesis of atherosclerosis.
Lipids are deposited on and in arterial walls causing
inflammation of the intima, followed by monocyte infil-
tration, leading to wall thickening and formation of
atherosclerotic plaques [7]. The interaction of monocytes
with proteins enriched in the plaque is of particular inter-
est as improvements in our understanding of this process
may enable the identification of novel therapeutic targets.
* Correspondence: steffen.eisenhardt@uniklinik-freiburg.de; karlheinz.
peter@bakeridi.edu.au
1Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
Full list of author information is available at the end of the article
Eisenhardt et al. Proteome Science 2011, 9:1
http://www.proteomesci.com/content/9/1/1
© 2011 Eisenhardt et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.These could potentially inhibit the uptake of lipopro-
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immune mediators by monocyte-derived macrophages.
This process leads to the formation of foam cells that
collectively contribute to atheroma formation. The pro-
teomic changes of THP-1 monocytes induced by CRP
isoforms have not been identified to date. In this study,
the hypothesis to be tested was that mCRP induces spe-
cific changes in the protein expression profile of THP-1
cells that promotes a pro-inflammatory phenotype. This
hypothesis was tested in an in vitro treatment - control
experimental design in which the effects of CRP iso-
forms and LPS on protein expression profiles were
determined.
Results
A 2D-SDS PAGE display of cell lysates from THP-1
cells is presented in Figure 1. Overall 12 gels were ana-
lyzed, for each treatment in triplicates, 493 to 508 pro-
tein spots were displayed. When displays from mCRP
and pCRP-treated THP-1 monocytes were compared 15
spots had at least 2-fold difference between pCRP and
mCRP and were further identified (Figure 1). Table 1
presents differentially expressed proteins that change >
2-fold in expression levels. Spots that were identified by
MALDI ToF mass spectrometry are presented in Figure
2. Figure 3 presents high magnification views of areas of
interest that changed significantly compared to the con-
trol group. Most notably proteins of the ubiquitin-
proteasome system and of the heat shock response are
up-regulated by mCRP. Specific proteins of interest are
listed in Table 2 with mean ± standard deviation, which
is also graphically shown in Figure 4. mCRP increases
the expression of UBE1, HSP 105, IF alpha and HSP 70
significantly when compared to control THP-1 cells,
suggesting increased cellular stress in this treatment
group. pCRP induces HSP 105 isoform beta expression,
as well as HSP 70 expression, albeit weaker than mCRP.
Interestingly, only LPS induces a significantly increased
expression of HSP 90.
ACTN4 and RIPK2 are increased in the LPS, as well
as in the m- and pCRP group. ENOA is increased by
LPS and mCRP stimulation of THP-1 monocytes.
Overall, the expression profiles of LPS, mCRP and
pCRP-treated cells differ significantly from the control
cells, as well as from each other. Other proteins that
were identified include several transcription-factors
and cell metabolism and signal transduction associated
proteins (see Table 1.), further indicating an increased
transcription and cell metabolism in the treatment
groups.
LPS, but not CRP, mediates effects via NF-B and
MAPKinase-signaling pathways
To investigate the mechanism underlying this difference
in expression profile NF-B and MAPKinase-signaling
pathways were investigated. Phosphorylation of key sig-
nal transduction enzymes was assessed for each study
group. The enzymes studied were c-Jun N-terminal
kinase (JNK), p38, extracellular signal-regulated kinase
(ERK), AKT8 virus oncogene cellular homolog (AKT)
and inhibitor of NF-B( I K B a). Results are shown in
Figure 5.
In the LPS treated group increased phosphorylation
of JNK, p38 and ERK and degradation of IKBa are
clearly shown consistent with previous studies [8].
However, there was no significant signal transduction
in either the mCRP or pCRP treated group through
these pathways when compared to control. Whilst this
does not demonstrate the signaling mechanism of
either CRP group, it is clear that it differs substantially
from that induced by LPS. This result is important
as it establishes that mCRP dialysis was effective
and that these results are not confounded by LPS
contamination.
Validation of proteins by Western blotting
Western blotting using specific antibodies confirmed the
protein identity of HSP90, HSP70, RIPK2, UBE1, HSP
105 and aACT4. A selection of the differentially
expressed proteins is shown in Figure 5. These results
further confirm the identity of the proteins as identified
by mass spectrometry.
Figure 1 P r o t e i ne x p r e s s i o no fP B S ,L P S ,m C R Pa n dp C R P -
treated THP-1 monocytes. Proteins from whole cell lysates were
separated on a pH 3-10 IPG strip in the first dimension and on a
SDS-polyacrylamide (12%) gel in the second dimension.
Representative Coomassie-stained gels for each treatment group are
shown.
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polystyrene flask
After various hours of incubation time samples of the
pCRP incubation assays were dot-blotted and the plots
probed with mCRP (clone 9C9) or pCRP (clone 8D8)
specific antibodies (Figure 6). pCRP staining shows a
slight decrease in intensity in the course of the experi-
ment, whereas mCRP positivity gradually increases. This
suggests a partial spontaneous dissociation of pCRP to
mCRP the protein that potentially influences the out-
come of the experiment.
Discussion
T h eh y p o t h e s i st ob et e s t e di nt h i ss t u d yw a st h a t
mCRP induces specific changes in the protein expres-
sion profile of THP-1 cells that potentially represent a
pro-inflammatory phenotype. An in vitro treatment-
control experimental design was used to determine
CRP isoform-specific effects on proteins isolated and
displayed using 2D SDS PAGE and MALDI Tof/Tof
analysis. The three major findings of this study are: (1)
mCRP and pCRP both induce changes in the protein
expression profile of THP-1 monocytes that can be
Table 1 Differentially expressed proteins in LPS-, mCRP- or pCRP-treated THP-1 monocytes
# Protein identified MW pI MOWSE score Cov. LPS mCRP pCRP
1 HSP90-beta 83554 4,97 162 40% 1,46 0,38 1,06
2 eukaryotic translation initiation factor 2(IF2A) 36374 5,02 76 27% 0,48 1,46 0,33
3 heterogeneous nuclear ribonucleoprotein F(hnRNP) 45985 5,38 65 18% 0,77 2,3 2,88
4 interferon regulatory factor 8 (IRF8) 49123 6,38 64 26% 0,35 0,32 0,48
5 HS105 isoform 1 97716 5,28 58 11% 2,02 2,71 1,61
6 HS105 isoform 2 97716 5,28 90 19% 1,94 1,43 3,1
7 alpha-actinin-4 (ACTN4) 105245 5,27 55 16% 3,26 2,66 3,69
8 HSP70 70280 5,48 75 18% 3,93 3,55 2,2
9 ubiquitin-activating enzyme E1 (UBE1) 118858 5,49 99 22% 1,12 2 1,39
10 deoxyuridine 5’-triphosphate nucleotidohyrolase
(DUT)
26975 9,65 70 28% 0,69 0,85 0,46
11 prohibitin (PHB) 29843 5,57 94 44% 36,16 35,12 30,07
12 DEAD box protein UAP56 49416 5,44 72 22% 0,73 0,6 2,32
13 interferon-induced GTP-binding protein Mx1 (Mx1) 75886 5,6 85 22% 2,09 1,14 1,19
14 signal transducer and activator of transcription 1-
alpha/beta (stat1)
87850 5,74 104 24% 2,06 1,2 1,24
15 neutral alpha-glucosidase AB precursor (GANAB)
isoform 1
107263 5,74 114 20% 0,77 0,44 0,9
16 neutral alpha-glucosidase AB precursor (GANAB)
isoform 2
107263 5,74 58 13% 1,75 4,56 1,3
17 receptor interacting serine-threonine protein kinase
2 (RIPK2)
61726 6,63 59 11% 2,35 2,43 2,44
18 sorting nexin-8 52935 6,96 55 16% 0,26 0,25 0,28
19 bifunctional purine biosynthesis protein (PUR9) 65089 6,27 85 29% 2,17 1,55 1,27
20 elongation factor 2 (EF-2) isoform 1 96246 6,41 129 23% 0,6 0,97 0,34
21 adenylyl cyclase-associated protein 1 (CAP1) 52222 8,27 88 31% 0,72 0,8 0,48
22 EH domain-containing protein 1 (Testilin) 60646 6,35 118 29% 2,32 1,47 1,36
23 far upstream element-binding protein 2 (FUBP2) 73063 8,02 77 17% 3,62 3,36 3,08
24 far upstream element-binding protein 2 (FUBP2) 73063 8,02 56 9% 0,01 0,01 0,01
25 6-phosphogluconate dehydrogenase (6PGD) 53619 6,8 56 20% 2,06 1,82 2,09
26 alpha-enolase (ENOA) 47481 7,01 61 37% 2,02 2,61 1,02
27 catalase 59947 6,9 102 40% 0,62 0,98 0,48
28 elongation factor 2 (EF-2) isoform 2 96246 6,41 70 14% 1,46 1,38 2,56
The MS spectra of protein digests were used to search the NCBInr database using the ProFound™ search engine. Protein names been assigned according to the
Swiss-Prot database. Differentially expressed proteins (ratio > 2) that were up-regulated or down-regulated in response to LPS, mCRP or pCRP for 18 h are listed.
The LPS, mCRP and pCRP columns correspond to the expression of each protein relative to its expression in control. Results presented are mean values for three
independent analyses performed for each condition. The spot numbers (#) are identical to those given in Figure 2. cov: coverage.
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Page 3 of 12Figure 2 Protein expression map of THP-1 monocytes. Spots that are differentially expressed in the three treatment groups were analysed
by MALDI-ToF. Protein identity of these proteins is given in the figure.
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changes that are distinct from pCRP, further support-
ing the concept of a distinct role of mCRP and pCRP
in vascular inflammatory diseases, including athero-
sclerosis. (3) LPS induced proteomic changes and LPS
induced signaling pathways differ from mCRP and/or
pCRP induced changes.
T h ec a u s a lr o l eo fC R Pi nt h ep a t h o p h y s i o l o g yo f
atherosclerosis is currently an area of great controversy.
In particular the existence of two isoforms mCRP and
pCRP have complicated the analysis and interpretation of
experimental findings. In vitro, pCRP has been reported
to increase IL-8 production in monocytes, [9] and to
increase monocyte adhesion to human aortic and
Figure 3 High-magnification areas of proteins differentially expressed. The middle section shows a representative Coomassie-stained gel of
proteins derived from control cells. Around the typical control gel, enlarged areas of interest derived from control cells, LPS, mCRP and pCRP
treated cells are shown. Protein spots of interests are encircled. The spot numbers are identical to those given in Figure 2.
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ditions[10,11]. However, several studies have also identi-
fied possible anti-inflammatory effects of pCRP [12], and
anti-atherosclerotic actions for mCRP [13]. In contrast to
pCRP, mCRP induces IL-8 secretion in neutrophils [3]
and human coronary artery endothelial cells (HCAEC)
[2], promotes neutrophil-endothelial cell adhesion [14],
delays apoptosis of human neutrophils [15]. Additionally,
both CRP conformations interact differently with compo-
nents of the complement cascade [16].
Recently, we identified a mechanism by which penta-
meric CRP is dissociated to monomeric CRP on activated
platelets, which is then deposited in atherosclerotic pla-
ques [1,17,18]. These findings support the concept of a
causal role for CRP in the development of atherosclerosis
that might be independent of CRP as a risk factor in
atherosclerosis associated cardiovascular events [19]. In
addition, we could show that mCRP induces monocyte
activation and adhesion to a far greater extent than
pCRP. Based on our previous findings we have investi-
gated the intracellular mechanisms involved resulting in
this current study.
The result of our proteomic analysis suggests that
mCRP has pro-inflammatory properties at the proteomic
level, recognizing the limitations of proteomic data in
predicting the functional relevance of up-regulation of
single proteins. One of our key findings is the up-regu-
lation of the ubiquitin-activating enzyme E1 (UAE1) by
mCRP, but not pCRP or LPS. This is of particular inter-
est as the role and the stimulation of the ubiquitin-pro-
teasome system (UPS) in atherosclerosis has been
suggested previously [20]. The UPS consists of several
enzymes which function to degrade proteins that are
presented by helper proteins, so called chaperones.
These chaperones assist in the post-translational folding
of proteins to their correct 3-D-structure, but also
recognize mis-folded proteins and present them for
degradation by the UPS [20,21]. Thus, the UPS-chaper-
one system assures the quality of intracellular proteins.
The coronary artery plaques associated with fatal acute
myocardial infarction are characterized by increased
expression of ubiquitinated proteins [22]. Similarly, car-
otid artery plaques from patients with symptoms of
focal cerebral ischemia display a higher level of ubiquiti-
nated proteins than those obtained from asymptomatic
patients [23,24].
The up-regulation of UAE1 in mCRP stimulated
monocytes may also be a sign of the induction of the
macrophagic differentiation process induced by mCRP,
as a crucial role for UAE1 in the differentiation process
and the associated nucleotide excision repair has been
recently described [25].
Both LPS [26] and mCRP [1] can induce reactive oxy-
gen species (ROS) in monocytes or THP-1 monocytes.
Therefore it is unlikely that the proteomic changes
observed in the treatment groups are mediated by ROS
as there is a substantial difference in the proteomic pro-
file of THP-1 cells treated with LPS and those treated
with mCRP. However, the induced oxidative stress can
lead to an increase in the expression of chaperones,
including those of the family of heat shock proteins
(HSPs). One of the HSPs that is most closely associated
with atherosclerosis is HSP 70, which is expressed in
atherosclerotic lesions [27]. In our proteomic analysis
we found a significantly increased expression of HSP70
in monocytes stimulated with mCRP compared to the
pCRP treated cells and PBS treated control cells. In
experimental models of ischemia and reperfusion injury
it has been suggested that HSP 70 mediates myocardial
protection [28,29]. Furthermore, HSP70 has been found
to be up-regulated in the proteome of monocytes in
acute coronary syndrome (ACS) [30], a disease in which
Table 2 Selected differentially expressed proteins are tabulated with mean values for three independent analyses and
standard deviation of spot density
spot# Protein control LPS mCRP pCRP
mean sd CV mean sd CV mean sd CV mean sd CV
1 HS90beta 12155 911,6 7,5 17762,2 1101,3 6,2 4658,7 195,7 4,2 12939,9 2368,0 18,3
4 IRF8 2857,2 734,3 25,7 988,2 175,9 17,8 923,3 36,0 3,9 1383,2 225,5 16,3
5 HS105 IFa 562,1 169,8 30,2 1133,5 240,3 21,2 1521,4 429,0 28,2 904,5 104,0 11,5
6 HS105 IFb 404,7 100,4 24,8 785 83,2 10,6 578,2 101,2 17,5 1256,2 374,3 29,8
7 ACTN4 971 153,4 15,8 3162,5 294,1 9,3 2584,7 615,2 23,8 3580,3 211,2 5,9
8 HSP70 1474,4 246,2 16,7 5791 1268,2 21,9 5237,8 361,4 6,9 3240,2 3,2 0,1
9 UBE1 1247,9 68,6 5,5 1398,1 423,6 30,3 2500,3 125,0 5 1728,7 34,6 2,0
17 RIPK2 905,2 18,1 2,0 2129,4 166,1 7,8 2198,9 281,5 12,8 2210,1 276,3 12,5
22 EHD1 347,4 40,6 11,7 807,2 17,0 2,1 510,2 34,2 6,7 472,3 91,2 19,3
26 ENOA 1255 25,1 2,0 2540,5 454,7 17,9 3272,3 618,5 18,9 1281,1 234,4 18,3
overall CV(n = 10 proteins) 14,2 14,5 12,8 13,4
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Page 6 of 12circulating CRP levels are increased as well. Our results
suggest that there is a potential interaction of HSP 70
with CRP that warrants further research.
Other HSPs differentially expressed are members of the
HSP 105 family. HSP 105 alpha and beta are alternatively
spliced products derived from the HSP 105 gene tran-
script. HSP 105 alpha is constitutively expressed but
transcription is increased in response to various stressors.
In contrast HSP 105 beta, which lacks 44 amino acids
from HSP 105 alpha, is specifically expressed during mild
heat shock [31]. These proteins can exist as complexes
associated with HSP 70 in mammalian cells [32]. Similar
to HSP 70, HSP 105 alpha and beta suppress the aggrega-
tion of denatured proteins caused by heat shock in vitro.
Figure 4 Quantitative analysis of differentially expressed
proteins. A. mCRP induces expression of cellular stress related
proteins of the ubiquitin/proteasome system and the heat
shock response. Expression levels of several proteins of interest
were quantified and are given in the graphs as mean +/- standard
deviation. # indicates p < 0.05 compared to control. mCRP up-
regulates UBE1, and HSP 70, as well as the alpha isoform of HSP 105.
pCRP induces the beta isoform of HSP105. B. Differential
expression of proteins involved in the inflammatory response.
ACTN4 and RIPK2 are increased in the LPS, as well as in the m- and
pCRP group. ENOA is increased by LPS and mCRP stimulation of THP-
1 monocytes, whereas EHD1 is significantly upregulated after
stimulation with LPS. C. Western blot analysis of selected proteins
that are differentially expressed in THP-1 cells. Selected Proteins
were validated by Western blotting. Western blot results are shown
exhibiting specific staining of 1D-gels with anti-HSP70, anti-RIPK2 and
anti-UBE1 antibodies. Analysis served as a confirmation of the protein
identity in addition to the Mass-spec analysis.
Figure 5 LPS, but not CRP, mediates effects via NF-Ba n d
MAPKinase-signaling pathways. In the LPS treated group
increased phosphorylation of JNK, p38 and ERK and degradation of
IKBa are detected by Western blotting. There is no significant signal
transduction in either the mCRP or pCRP treated group through
these pathways when compared to control. This result
demonstrates that p- and mCRP are not sharing these signal
transduction pathways with LPS and that the results of this study
are not confounded by LPS contamination.
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can function as a substitute for HSP 70 to suppress the
aggregation of denatured proteins in cells under severe
stress, in which cellular ATP levels are elevated [33].
Overall, the up-regulation of these proteins could poten-
tially indicate cellular stress, induced by CRP stimulation
of THP-1 monocytes. Interestingly, the differential
expression of HSP 105 alpha is induced by mCRP,
whereas pCRP induces expression of HSP 105 beta,
further supporting our concept of discrete function and
effects of mCRP and pCRP.
Other proteins increased in the treatment groups that
are associated with the inflammatory response include
alpha-enolase, alpha-actinin 4 (ACTN4) and EH domain
containing protein 1 (EHD1 = Testilin). Alpha-enolase
is significantly and uniquely increased after mCRP treat-
ment. Alpha-enolase serves as a plasminogen receptor
on macrophages and therefore has an important func-
tion in inflammatory cell recruitment [34]. In respect to
the development of atherosclerosis, cholesterol loading
of macrophages induces expression of alpha-enolase in
mice [35].
ACTN4, as a non-muscle alpha-actinin, is function-
ally important for leukocyte diapedesis in endothelial
cells [36] and as such important for cell motility in
inflammation. In addition, it has been detected in lipid
rafts of THP-1 monocytes, and an involvement in vesi-
cular trafficking and phagosome formation has been
suggested [37].
EHD1 regulates the endosomal transport of beta-1
integrins [38], which are important cell adhesion
receptors involved in adhesion and transmigration of
inflammatory cells [39]. It is significantly up-regulated
in LPS stimulated THP-1 monocytes, but not in cells
incubated with CRP isoforms further underlining the
differentiated proteomic response of these cells to LPS
versus CRP co-incubation that cannot be attributed to
the contamination of the CRP preparations with LPS,
as suggested for other experiments [40].
Overall, the proteins up-regulated by the CRP iso-
forms potentially represent the induction of a pro-
inflammatory monocytic phenotype for adhesion cell
recruitment and transmigration into the area of
inflammation.
A recent comprehensive genomic study of human pri-
mary monocytes by Hanriot et al. [12] demonstrated
complex cellular responses, both pro- and anti-inflam-
matory, following stimulation by (p)CRP. Amongst other
findings chemokines (Gro protein alpha and beta, Inter-
leukin (IL)-8), cytokines (IL-1 alpha and beta, IL-6, IL-
19), integrins (Integrin alpha 6 and beta 1), Liver X
receptor alpha and MAPK 8 were all up-regulated.
Interestingly these authors also found a down regulation
of several pro-inflammatory chemokines, suggesting
potential anti-inflammatory effects of (p)CRP in primary
monocytes at the genomic level.
Our proteomic dataset derived from a monocytic cell
line complements these findings. The increased expres-
sion of Alpha-enolase and ACTN4 identified in our
work is consistent with the up-regulation of several
genes discussed above that encode for proteins involved
in leukocyte trafficking, adhesion and transmigration by
Hanriot et al. [12]. The increased expression of these
genes and proteins potentially characterizes a pro-
inflammatory phenotype induced by (p)CRP.
CRP is generally believed to bind to receptors of the
Fc gamma Receptor family [41]. Recently it has been
shown that lipid rafts are involved in mCRP signal
transduction [1,42]. The proteomic expression model
used in this study involving prolonged incubation per-
iods was not able to identify a discrete receptor ligand
interaction. Successful resolution of this question will
most likely require development of dedicated cell
models and remains an area of active ongoing
research.
One potential limitation of our study is the use of
THP-1 cells, instead of primary monocytes. THP-1 cells
could potentially reveal different properties compared to
the primary cells. However, THP-1 cells have been
previously used as a surrogate for primary monocytes,
particularly in proteome research, and their use has so
far contributed towards several pathophysiologically
important findings, specifically in the field of athero-
sclerosis research [43]. Therefore, although our findings
must be interpreted with this in mind it does not invali-
date this data.
Figure 6 Incubation of pCRP in polystyrene flasks leads to a
partial dissociation of the protein to mCRP. After various hours
of incubation time samples of the incubation assays with pCRP
were dot-blotted and the blots probed with mCRP (clone 9C9) or
pCRP (clone 8D8) specific antibodies. Whereas the pCRP staining
shows a mild decrease the mCRP staining increases gradually in the
course of the experiment.
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showed significant less pro-inflammatory properties
compared to mCRP, our findings in this proteomic
study are surprising, as pCRP induces some pro-inflam-
matory proteomic changes as well. This may be due to
one of the following factors. In our previous work we
examined the short-term effects of the two isoforms on
monocytes, which is fundamentally different from the
18 hours incubation period that is necessary to evaluate
proteomic changes in the set of experiments described
herein. Secondly, as the incubation was carried out in
polystyrene tissue culture dishes spontaneous dissocia-
tion of pCRP to mCRP may occur over the course of
the experiment. Indeed such dissociation has been
described previously on polystyrene materials [44] and
was confirmed by us. Therefore some effects seen in
pCRP treated cells may indeed be effects caused by
mCRP, which could potentially influence the outcome
of the experiments and warrants further investigations
into the distinct properties of the two isoforms.
Conclusions
This study confirms the distinct properties of mCRP
and pCRP. In particular, mCRP related changes of the
THP-1 proteome are mainly associated with the heat-
shock response. These results are consistent with a
pathophysiological role of mCRP in inflammatory dis-
ease and identify a number of novel target proteins that
are involved in the changes occurring in monocytes
upon activation by CRP isoforms. These potentially
represent novel therapeutic targets and may be of parti-
cular relevance for monocyte activation by CRP in the
vicinity of atherosclerotic plaques and in the potential of
therapeutic targeting of mCRP in vascular disease.
Methods
Culture, stimulation and harvesting of THP-1 cells
Human THP-1 cells were grown in RPMI 1640 medium
containing 10% fetal bovine serum (FBS), 2 mM gluta-
mine, 10 mM HEPES, 1 mM sodium pyruvate, 561025
M b-mercaptoethanol, penicillin (100 U/mL), and strep-
tomycin (100 mg/mL) and stored at 37°C in an atmo-
sphere of 5% CO2.
C e l l sw e r es e e d e da tad e n s i t yo f6×1 0
5 cells/mL in
medium containing 10% FBS. The cells were pre-incu-
bated in serum-free medium for 24 h and then treated
with PBS, mCRP (25 μg/mL), pCRP (25 μg/mL) or
100 ng/ml LPS (Sigma) for 18 h. mCRP was prepared as
described previously [1], pCRP was from Calbiochem and
dialyzed extensively against PBS prior to use.
Intracellular signaling analysis
Human THP-1 cells were grown as described above.
Cells were seeded at a density of 1×10
6 cells/mL in
medium containing 3% FBS for 24 hours prior to treat-
ment with PBS, mCRP, pCRP or LPS as above. Initial
experiments were performed at multiple time points (0,
15, 30, 60 or 120 minutes) to assess when activity
changes could most reliably be found. For all published
data experiments were ceased at 60 minutes. After sti-
mulation cells were collected, pelleted by centrifugation
at 3,000 G for 5 minutes, washed in 4°C phosphate buf-
fered saline (PBS) and pelleted again. PBS was then
removed and cells were lysed for 10 minutes at 4°C in
80 μL lysis buffer containing 50 mM Tris, 130 mM
N a C l ,5m ME D T A ,1 %N P - 4 0 ,1m MP M S F ,1m M
NaF, protease and phosphatase inhibitor. Cellular debris
was pelleted by centrifugation at 16,000 G for 30 min-
utes at 4°C. Supernatant was then collected, protein
concentration measured by BCA at 570 nm and stored
at -80°C prior to further analysis.
1D SDS Polyacrylamide Gel Electrophoresis (SDS PAGE)
30 ug of measured protein sample was combined with
Laemmli buffer, denatured for 5 minutes at 95°C and
loaded on to 10% SDS PAGE gels. Samples underwent
semi-dry transfer to nitrocellulose membrane and were
probed for alteration in gene expression as shown. Phos-
phorylated and total protein loads are shown for each
kinase except IKBa, which is ubiquitinated and
degraded following activation. All antibodies were
obtained from Cell Signaling Technology, USA. Results
shown are representative blots performed in triplicate of
individual experiments which were each performed at
least three times.
Sample Preparation
Cells were harvested at 1400 g for 10 min and washed
3 times with PBS. Cell pellets were lysed using 4%
CHAPS, 7 M urea, 2 M thiourea, supplemented with
4.6 mM PMSF, 25 μg/mL RNAse (MP Biomedicals,
NSW, Australia), 100 μg/mL DNAse (MP Biomedicals),
44 mM MgCl2. Total protein content of each sample
was determined using the Coomassie
® Plus Protein
Assay Reagent Kit (Pierce Biotechnology, USA).
Two-Dimensional SDS Polyacrylamide Gel Electrophoresis
(SDS PAGE)
A total of 50 μg protein was loaded onto first dimension
Ready Strip™ gels (11 cm, pH 5-8; Bio-Rad Laboratories,
Hercules, CA, USA) following sample solubilisation with
200 μL of multiple chaotrope solubilisation solution
(7 mol/L urea, 2 mol/L thiourea, 100 mmol/L dithio-
threitol, 4% CHAPS, 40 mmol/L Tris buffer, 0.5% carrier
ampholytes pH 3-10, trace bromophenol blue). Strips
were actively rehydrated at 50 V at 20°C for 16 h. Pro-
teins were isoelectrically focused at 250 V for 15 min
and then slowly ramped to 8000 V for 150 min and
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total of 42 000 Vh per gel). The IPG strip was equili-
brated twice for 15 min with gentle agitation in 6 mL of
equilibration solution (0.1% Tris-HCl (pH 6.8), 5.5 M
urea, 0.3% glycerol, 0.035 M SDS and 0.065 M DTT).
DTT was replaced with iodoacetamide (14 mM) and
traces of Bromophenol Blue for the second equilibration
solution. Second dimension separation was performed
on precast 10.5-14% Tris-HCl Criterion Gels (Bio-Rad
Laboratories). Gels were electrophoresed at 10 mA/gel
for 1 h, 20 mA/gel for 2 h and then 30 mA/gel for
30 min. Gels were then fixed in methanol/acetic acid
(10%) for 1 h then stained in SYPRO Ruby
® fluorescent
protein dye (Bio-Rad Laboratories) at room temperature
for 16 h on a rocking platform. Gels were destained for
1 h in methanol/acetic acid (10%/7%). Gels were indivi-
dually scanned using an FX imager with a 532-nm laser
at 100 μm resolution (Bio-Rad Laboratories). The pro-
tein spots were detected, quantified, and matched using
PDQuest V7.3.1 (Bio-Rad Laboratories). Each gel was
normalized to the total quantity of valid spots. The gels
were then counterstained with colloidal Coomassie bril-
liant blue (CBB) to enable visualization and manual
excision. 2D-PAGE and cell seeding was performed in
triplicate for each treatment.
In-Gel Digestion and Peptide Analysis Using Matrix-
Assisted Laser Desorption-Ionization Time-of-Flight Mass
Spectrometry
In this study, a MALDI Autoflex II, Bruker Biosciences
mass spectrometer was used to estimate peptide masses
generated from the in-gel digestion of the 2D PAGE
protein spots. The database search results and tabulated
protein identifications are from data collected from the
mass spectrometer. Only high scoring and confident hits
retrieved from the selected databases using Mascot
search engine are tabulated. Selected protein spots were
manually excised from colloidal CBB-stained 2D gels
using a spot picker (The Gel Company, San Francisco,
CA, USA, picker head, 1.5-mm diameter). The gel plugs
were rinsed by transfer into 96-well plates (Greiner Bio-
One BioScience, NC, USA) containing deionized water
(100 μl per well, MilliQ grade). Digestion using trypsin
with subsequent application to a Matrix Assisted Laser
Desorption-Ionization Time-of-Flight (MALDI-ToF) tar-
get plate (Bruker Daltronics, Bremen, Germany) was
performed robotically with an Ettan Spot Handling
workstation (GE Healthcare, Uppsala, Sweden). The gel
plugs were destained in 100 μlo f5 0m Ma m m o n i u m
bicarbonate (Riedel-de Haen, Germany)/50% methanol
(Lab-Scan Analytical Sciences, Gliwice, Poland) for
30 min, then washed three times in deionized water
(100 μl, 5 mins, Milli Q grade). Gel plugs were then
incubated in 100 μl of 50 mM ammonium bicarbonate/
50% methanol for 30 min followed by incubation in 100
μl of 75% acetonitrile (ACN, Lab-Scan Analytical
Sciences, Ireland) for a further 30 min. After drying the
gel plugs (40°C, 23 min), 10 μl of sequencing grade tryp-
sin solution (20 ng/μl, Promega, Madison, WI, USA)
dissolved in 20 mM ammonium bicarbonate was added
and incubated (37°C for 60 min). During the following
extraction step, gel plugs were covered with 60 μl0 . 1 %
trifluoroacetic acid (TFA, Pierce, Rockford, USA)/50%
ACN and incubated for 20 min. The peptide containing
supernatant was transferred to a new 96-well plate, and
the extraction was repeated (40 μl). The supernatants
were pooled and dried (40°C for 3 h). The peptides were
resolubilized by manually adding 50% ACN/0.1% TFA
(15 μl) into each well and gently vortexing (10 mins,
Vortex Genie 2). The resolubilized peptide mixtures (0.3
μl) were each combined with MALDI matrix (1.0 μl,
a-cyano-4-hydroxy cinnamic acid, 3 mg/ml in acetone/
ethanol (1:2, v/v), Bruker Daltronics) and applied
(1.3 μl) to the Anchorchip target plate using the Ettan
Spot Handling robotic workstation (GE Healthcare). The
peptide-matrix samples were allowed to dry on the
target plates (10-15 min) before data collection.
MS Data Collection, Database Searching, and Protein
Identification
General instrument settings for the Autoflex II MALDI-
ToF/ToF (Bruker Daltronics) are as follows: mode, posi-
tive, and reflector; pulsed ion extraction, 120 ns; laser
intensity, 22-28%; laser frequency, 25 Hz; 600 laser
shots were collected and summed for all MS data. The
mass range (800-3,000 m/z) of the mass spectrometer
was internally calibrated using the autolytic peaks of
trypsin (842.510 and 2,211.104 m/z). Matrix was sup-
pressed using a high-gating factor. Signal suppression
below 800 m/z was activated. Data acquisition and pro-
cessing was performed using instrument-specific soft-
ware, Flex-Control, FlexAnalysis, and BioTools software
(Bruker Daltonics). Peaklists were generated before
database searching. Data collected from the Autoflex II
MALDI ToF/ToF, was submitted to the SwissProt
database (release 51.0, 31October 2006) using the
Mascot search algorithm (Matrix Science, http://www.
matrixscience.com). Typical search parameters were as
follows: mass tolerance, 0.5 Da; missed cleavages, 2;
enzyme, trypsin; fixed modifications, carbamidomethyla-
tion; variable modification, Oxidation (M); taxonomy,
Homo Sapiens.
Validation of proteins by Western blotting
Antibodies and reagents
Monoclonal antibodies against Hsp90 were obtained
from BD Biosciences (California, USA), RIPK2 (clone
7F5) Abnova (Taiwan) Corporation and aACT4(7H6)
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HSP105 was obtained from MBL (Woburn, MA, USA),
UBE1 from Atlas Antibodies (Stockholm, Sweden) and
Hsp70(Hsp72) from Stressgen (MI, USA). Horseradish
peroxidase-conjugated goat anti-mouse antibody was
obtained from Bio-Rad Laboratories while HRP-conju-
gated donkey anti-rabbit antibody was from Amersham
Biotechnology (Uppsala, Sweden).
The identity of all proteins of interest from mass spec-
trometry data were confirmed by Western blotting and
probing with specific antibodies. All samples were
reduced with 2% beta-Mercaptoethanol and 20 μg/sam-
ple was applied to 10% criterion pre-cast gels (BioRad
Laboratories). Resolved proteins were transferred to
nitrocellulose membranes and probed with primary anti-
body followed by peroxidase-labelled secondary antibody
and visualized by enhanced chemiluminescence (ECL)
(Amersham, Buckinghamshire, UK) detection system
according to the manufacturer’s instructions. Dual preci-
sion MW marker (BioRad Laboratories) was used to
determine the correct band size. Band density was eval-
uated by Quantity One software (BioRad Laboratories).
Monitoring CRP dissociation by dot-blotting
Samples of the incubation experiments were taken after
t h e6 ,1 2a n d1 8h o u r so ft h ee x p e r i m e n ta n dd o t -
blotted by a BioRad 96-well Dot Blot apparatus (Bio-
Rad Laboratories) onto nitrocellulose membranes
according to the manufacturers instructions. Membranes
were probed for mCRP expression by mCRP specific
antibodies (clone 9C9) as described previously [1].
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